Published in Chem Rev on February 11, 2016
Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator. Angew Chem Int Ed Engl (2016) 0.77
Bulk Surfaces Coated with Triangular Silver Nanoplates: Antibacterial Action Based on Silver Release and Photo-Thermal Effect. Nanomaterials (Basel) (2017) 0.75
Cytotoxicity of Pyrazine-Based Cyclometalated (C^N(pz)^C)Au(III) Carbene Complexes: Impact of the Nature of the Ancillary Ligand on the Biological Properties. Inorg Chem (2017) 0.75
Beyond chemotherapeutics: cisplatin as a temporary buckle to fabricate drug-loaded nanogels. Chem Commun (Camb) (2017) 0.75
Esophageal cancer: The latest on chemoprevention and state of the art therapies. Pharmacol Res (2016) 0.75
Oxidative Stress Induced by Pt(IV) Pro-drugs Based on the Cisplatin Scaffold and Indole Carboxylic Acids in Axial Position. Sci Rep (2016) 0.75
Linker design for the modular assembly of multifunctional and targeted platinum(ii)-containing anticancer agents. Dalton Trans (2016) 0.75
In vitro evaluation of folic acid-conjugated redox-responsive mesoporous silica nanoparticles for the delivery of cisplatin. Int J Nanomedicine (2016) 0.75
Metal complexes in cancer therapy - an update from drug design perspective. Drug Des Devel Ther (2017) 0.75
The Platin-X series: activation, targeting, and delivery. Dalton Trans (2016) 0.75
Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway. Drug Des Devel Ther (2016) 0.75
Developing multisite empirical force field models for Pt(II) and cisplatin. J Comput Chem (2016) 0.75
High cytotoxicity of vanadium(IV) complexes with 1,10-phenanthroline and related ligands is due to decomposition in cell culture medium. J Biol Inorg Chem (2017) 0.75
A pH responsive complexation-based drug delivery system for oxaliplatin. Chem Sci (2017) 0.75
The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials. Chem Soc Rev (2017) 0.75
The Differential Distribution of RAPTA-T in Non-Invasive and Invasive Breast Cancer Cells Correlates with Its Anti-Invasive and Anti-Metastatic Effects. Int J Mol Sci (2017) 0.75
In Vitro and in vivo Evaluation of Electrochemotherapy with trans-platinum Analogue trans-[PtCl2(3-Hmpy)2]. Radiol Oncol (2017) 0.75
Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer. Drug Des Devel Ther (2017) 0.75
Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 17.80
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release (2000) 14.89
Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov (2008) 12.72
The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer (2007) 12.38
Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov (2005) 9.47
AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science (1997) 8.05
Impact of nanotechnology on drug delivery. ACS Nano (2009) 6.87
INHIBITION OF CELL DIVISION IN ESCHERICHIA COLI BY ELECTROLYSIS PRODUCTS FROM A PLATINUM ELECTRODE. Nature (1965) 6.02
Platinum compounds: a new class of potent antitumour agents. Nature (1969) 5.92
Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chem Rev (1999) 5.63
Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res (1989) 5.62
p53 mutations in cancer. Nat Cell Biol (2013) 5.18
Antibody therapy of cancer. Nat Rev Cancer (2012) 5.17
Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci (2006) 5.15
Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev (2006) 5.08
Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst (1989) 4.97
Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem (2005) 4.65
Specific recognition of cruciform DNA by nuclear protein HMG1. Science (1989) 4.44
The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials (2000) 4.42
Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine (2006) 4.08
Targeting of drugs and nanoparticles to tumors. J Cell Biol (2010) 4.07
HMG1 and 2, and related 'architectural' DNA-binding proteins. Trends Biochem Sci (2001) 4.06
Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res (1977) 4.02
Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A (1998) 3.89
Three-dimensional aqueous-derived biomaterial scaffolds from silk fibroin. Biomaterials (2005) 3.87
Glucose metabolism and cancer. Curr Opin Cell Biol (2006) 3.75
Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry (1985) 3.67
Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res (1992) 3.66
Direct cellular responses to platinum-induced DNA damage. Chem Rev (2007) 3.42
The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene (2003) 3.10
Quantum-sized carbon dots for bright and colorful photoluminescence. J Am Chem Soc (2006) 3.08
Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev (2003) 3.07
The role of DNA mismatch repair in platinum drug resistance. Cancer Res (1996) 2.88
Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev (2000) 2.85
Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. J Am Chem Soc (2007) 2.82
Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science (1992) 2.79
Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm Res (1991) 2.70
Influence of the blood glucose concentration on FDG uptake in cancer--a PET study. J Nucl Med (1993) 2.66
Crystal structure of a bacterial homologue of glucose transporters GLUT1-4. Nature (2012) 2.64
Bisphosphonates: a review of their pharmacokinetic properties. Bone (1996) 2.52
The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans (2010) 2.48
Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device. J Am Chem Soc (2008) 2.40
Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res (2006) 2.37
Ultrasmall reduced graphene oxide with high near-infrared absorbance for photothermal therapy. J Am Chem Soc (2011) 2.36
Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer (1998) 2.29
Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun (2004) 2.29
Cross-linked block copolymer micelles: functional nanostructures of great potential and versatility. Chem Soc Rev (2006) 2.26
Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer (2008) 2.21
Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci U S A (2010) 2.21
Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads. J Am Chem Soc (2009) 2.16
Translocator protein/peripheral benzodiazepine receptor is not required for steroid hormone biosynthesis. Endocrinology (2013) 2.16
Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci U S A (2011) 2.16
International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev (2006) 2.15
HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci U S A (1994) 2.12
Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer (1993) 2.10
DNA polymerase zeta (pol zeta) in higher eukaryotes. Cell Res (2008) 2.02
Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol (2010) 1.99
Fluorescent carbon nanoparticles derived from candle soot. Angew Chem Int Ed Engl (2007) 1.98
Nanoscale coordination polymers for platinum-based anticancer drug delivery. J Am Chem Soc (2008) 1.97
Inhibition of transcription by platinum antitumor compounds. Metallomics (2009) 1.88
Metal-organic frameworks and self-assembled supramolecular coordination complexes: comparing and contrasting the design, synthesis, and functionality of metal-organic materials. Chem Rev (2012) 1.87
Error-prone translesion synthesis mediates acquired chemoresistance. Proc Natl Acad Sci U S A (2010) 1.85
Microfluidic platform for controlled synthesis of polymeric nanoparticles. Nano Lett (2008) 1.80
HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer (2004) 1.79
Recognition of cisplatin adducts by cellular proteins. Mutat Res (2001) 1.78
High-throughput synthesis and screening of platinum drug candidates. J Biol Inorg Chem (2000) 1.75
Reflections on the discovery and significance of estrogen receptor beta. Endocr Rev (2005) 1.75
2.4 A crystal structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-link in a DNA dodecamer duplex. Inorg Chem (2001) 1.71
Binding of cis- and trans-dichlorodiammineplatinum(II) to DNA: evidence for unwinding and shortening of the double helix. Science (1979) 1.70
Base-pair substitution hotspots in GAG and GCG nucleotide sequences in Escherichia coli K-12 induced by cis-diamminedichloroplatinum (II). Proc Natl Acad Sci U S A (1981) 1.66
Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. Chem Biol (2004) 1.66
Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res (2006) 1.65
DNA interstrand cross-links of trans-diamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues. Proc Natl Acad Sci U S A (1993) 1.65
cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects. Proc Natl Acad Sci U S A (2008) 1.62
Postsynthetic modifications of iron-carboxylate nanoscale metal-organic frameworks for imaging and drug delivery. J Am Chem Soc (2009) 1.61
Platinum-induced filamentous growth in Escherichia coli. J Bacteriol (1967) 1.56
Synergistic effect of chemo-photothermal therapy using PEGylated graphene oxide. Biomaterials (2011) 1.51
Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol (1993) 1.50
Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol (1998) 1.50
The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum(IV) complexes. J Biol Chem (1967) 1.50
Gold nanorods: their potential for photothermal therapeutics and drug delivery, tempered by the complexity of their biological interactions. Adv Drug Deliv Rev (2011) 1.48
Registries and registration of clinical trials. N Engl J Med (2005) 1.48
Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile. Proc Natl Acad Sci U S A (2012) 1.48
Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature. Bioconjug Chem (2007) 1.46
Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci U S A (2000) 1.46
Crystal structure of a naturally occurring parallel right-handed coiled coil tetramer. Nat Struct Biol (2000) 1.46
Cisplatin binding sites on human albumin. J Biol Chem (1998) 1.45
Lectins as pattern recognition molecules: the effects of epitope density in innate immunity. Glycobiology (2009) 1.45
Highly photoluminescent carbon dots for multicolor patterning, sensors, and bioimaging. Angew Chem Int Ed Engl (2013) 1.44
Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate. Proc Natl Acad Sci U S A (2009) 1.43
Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res (1993) 1.42
DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. Prog Nucleic Acid Res Mol Biol (2002) 1.39
X-ray structure and mechanism of RNA polymerase II stalled at an antineoplastic monofunctional platinum-DNA adduct. Proc Natl Acad Sci U S A (2010) 1.39
Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin. Biochemistry (1990) 1.38
Bisphosphonates in cancer therapy. Cancer Lett (2007) 1.36
A non-cross-linking platinum-acridine agent with potent activity in non-small-cell lung cancer. J Med Chem (2008) 1.36
Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res (2006) 1.35
Bending studies of DNA site-specifically modified by cisplatin, trans-diamminedichloroplatinum(II) and cis-[Pt(NH3)2(N3-cytosine)Cl]+. Biophys Chem (1990) 1.34
Monofunctional and higher-valent platinum anticancer agents. Inorg Chem (2013) 1.13
Effects of monofunctional platinum agents on bacterial growth: a retrospective study. J Am Chem Soc (2013) 0.87
The chiral potential of phenanthriplatin and its influence on guanine binding. J Am Chem Soc (2014) 0.85
Tobacco Mosaic Virus Delivery of Phenanthriplatin for Cancer therapy. ACS Nano (2016) 0.82
Metal-Based Optical Probes for Live Cell Imaging of Nitroxyl (HNO). Acc Chem Res (2015) 0.80
Coupling Oxygen Consumption with Hydrocarbon Oxidation in Bacterial Multicomponent Monooxygenases. Acc Chem Res (2015) 0.79
Phenanthriplatin Acts As a Covalent Poison of Topoisomerase II Cleavage Complexes. ACS Chem Biol (2016) 0.75
Single Turnover Reveals Oxygenated Intermediates in Toluene/o-Xylene Monooxygenase in the Presence of the Native Redox Partners. J Am Chem Soc (2015) 0.75
Reaction-Based Probes for Imaging Mobile Zinc in Live Cells and Tissues. ACS Sens (2015) 0.75
Chemical Approach to Positional Isomers of Glucose-Platinum Conjugates Reveals Specific Cancer Targeting through Glucose-Transporter-Mediated Uptake in Vitro and in Vivo. J Am Chem Soc (2016) 0.75
Tuning the Diiron Core Geometry in Carboxylate-Bridged Macrocyclic Model Complexes Affects Their Redox Properties and Supports Oxidation Chemistry. Inorg Chem (2017) 0.75
Achieving Reversible Sensing of Nitroxyl by Tuning the Ligand Environment of Azamacrocyclic Copper(II) Complexes. J Am Chem Soc (2016) 0.75